Daniel P. Rakiec
Publications by Year
Research Areas
Melanoma and MAPK Pathways, CRISPR and Genetic Engineering, Protein Degradation and Inhibitors, Cutaneous Melanoma Detection and Management, Cancer Research and Treatments
Most-Cited Works
- → An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)(2013)558 cited
- → Studying clonal dynamics in response to cancer therapy using high-complexity barcoding(2015)521 cited
- → CRISPR Screens Provide a Comprehensive Assessment of Cancer Vulnerabilities but Generate False-Positive Hits for Highly Amplified Genomic Regions(2016)395 cited
- → Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss(2018)356 cited
- → Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma(2013)328 cited
- → Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer(2019)211 cited
- → FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors(2015)105 cited
- → A Homozygous Mutation in the Tight-Junction Protein JAM3 Causes Hemorrhagic Destruction of the Brain, Subependymal Calcification, and Congenital Cataracts(2010)104 cited
- → CHMP1A encodes an essential regulator of BMI1-INK4A in cerebellar development(2012)104 cited
- → The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer(2019)91 cited